<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">MRP</journal-id><journal-title-group><journal-title>Medical Research and Practice</journal-title></journal-title-group><issn>2993-9690</issn><eissn>2993-9704</eissn><publisher><publisher-name>Art and Design</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.61369/MRP.2025050010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>乳腺癌肺转移瘤合并原发性肺癌：一例病例报道</title><url>https://artdesignp.com/journal/MRP/3/5/10.61369/MRP.2025050010</url><author>王嘉维,孙智超,王玲,陈丹,顾春东,赵士磊</author><pub-date pub-type="publication-year"><year>2025</year></pub-date><volume>3</volume><issue>5</issue><history><date date-type="pub"><published-time>2025-05-20</published-time></date></history><abstract>在临床实践中乳腺癌肺转移瘤同时合并原发性肺癌的情况极为罕见，目前治疗方式缺乏相应的循证医学证据。本案例报道了一例55岁中年女性患者，既往8年前因&amp;ldquo;右侧乳腺浸润性导管癌&amp;rdquo;而接受右侧乳腺癌根治术，术后接受了规范的化放疗和内分泌治疗；今患者因&amp;ldquo;右肺上叶肿物（两病灶）&amp;rdquo;而接受3D胸腔镜下右肺上叶切除术联合系统性纵隔内淋巴结清扫术。术后病理学检查显示一病灶为乳腺癌肺转移瘤、另一病灶为肺原发浸润性腺癌。本案例追溯了患者整个诊治过程，综合运用影像、免疫组化和分子病理检测等手段，多维度的鉴别了右肺上叶多个病灶的分子遗传特征及来源，进而能够为临床治疗提供更为精确的指导，优化治疗方案，提高治疗效果。</abstract><keywords>乳腺癌,肺转移瘤,原发性肺癌</keywords></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>&amp;nbsp;[1]Kurniawan BN, Ferianto D, Pieter J Jr. Evaluation of breast cancer metastasis and mortality rates based on molecular subtype: A description study. Breast Dis. 2022. 41(1): 427-432.&amp;nbsp;[2]Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008. 68(9): 3108-14.&amp;nbsp;[3]Dan Z, Cao H, He X, et al. A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer. Theranostics. 2016. 6(3): 435-45.&amp;nbsp;[4]Tao Z, Li T, Feng Z, et al. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. Front Oncol. 2020. 10: 1023.&amp;nbsp;[5]Oliveira AM, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol. 2005. 124 Suppl: S16-28.&amp;nbsp;[6]Mehdi A, Attias M, Arakelian A, Piccirillo CA, Szyf M, Rabbani SA. Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor&amp;nbsp;Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone. Cancers (Basel). 2022. 15(1): 48.&amp;nbsp;[7]Nishiyama N, Iwata T, Nagano K, et al. Lung metastases from various malignancies combined with primary lung cancer. Gen Thorac Cardiovasc Surg. 2010. 58(10): 538-41.&amp;nbsp;[8]Shih J, Bashir B, Gustafson KS, et al. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung&amp;nbsp;Primary. J Natl Compr Canc Netw. 2015. 13(8): 947-52.&amp;nbsp;[9]Wang W, Belosay A, Yang X, et al. Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells. Clin Exp&amp;nbsp;Metastasis. 2016. 33(5): 475-85.&amp;nbsp;[10]Fuke A, Tabei I, Okamoto T, Takeyama H. Complete remission from peritoneal metastasis of late recurrent breast cancer by endocrine therapy: a case report. Surg Case&amp;nbsp;Rep. 2020. 6(1): 313.&amp;nbsp;[11]de Ba&amp;egrave;re T, Aup&amp;eacute;rin A, Deschamps F, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases.&amp;nbsp;Ann Oncol. 2015. 26(5): 987-991.&amp;nbsp;[12]Vogl TJ, Naguib NN, Gruber-Rouh T, Koitka K, Lehnert T, Nour-Eldin NE. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases. Radiology. 2011. 261(2): 643-51.&amp;nbsp;[13]de Baere T, Tselikas L, Woodrum D, et al. Evaluating Cryoablation of Metastatic Lung Tumors in Patients--Safety and Efficacy: The ECLIPSE Trial--Interim Analysis&amp;nbsp;at 1 Year. J Thorac Oncol. 2015. 10(10): 1468-74.&amp;nbsp;[14]Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011. 8(6): 378-82.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
